Almotriptan is a selective 5-HT1B and 5-HT1D receptor agonist. These receptors mediate vasoconstriction of certain cranial vessels, as demonstrated in studies using isolated human tissue preparations.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
$substanceName is the active ingredient of these drugs:
Finland France Germany Ireland Italy
Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):